Beta Bionics, Inc. (NASDAQ:BBNX - Get Free Report) insider Mark Hopman sold 856 shares of the company's stock in a transaction that occurred on Tuesday, December 2nd. The stock was sold at an average price of $29.34, for a total value of $25,115.04. Following the completion of the sale, the insider owned 138,277 shares in the company, valued at $4,057,047.18. The trade was a 0.62% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link.
Mark Hopman also recently made the following trade(s):
- On Wednesday, March 4th, Mark Hopman sold 353 shares of Beta Bionics stock. The shares were sold at an average price of $11.57, for a total value of $4,084.21.
- On Monday, March 2nd, Mark Hopman sold 834 shares of Beta Bionics stock. The shares were sold at an average price of $12.36, for a total value of $10,308.24.
Beta Bionics Trading Up 4.6%
Beta Bionics stock opened at $10.87 on Tuesday. Beta Bionics, Inc. has a 12 month low of $8.89 and a 12 month high of $32.71. The company has a market capitalization of $482.41 million, a price-to-earnings ratio of -5.57 and a beta of 5.59. The business's fifty day simple moving average is $15.15 and its two-hundred day simple moving average is $22.01.
Beta Bionics (NASDAQ:BBNX - Get Free Report) last issued its quarterly earnings results on Tuesday, February 17th. The company reported ($0.30) earnings per share for the quarter, beating the consensus estimate of ($0.42) by $0.12. The firm had revenue of $32.12 million during the quarter. Beta Bionics had a negative return on equity of 20.29% and a negative net margin of 73.02%.
Institutional Trading of Beta Bionics
Hedge funds have recently bought and sold shares of the company. Caitong International Asset Management Co. Ltd lifted its holdings in Beta Bionics by 1,075.7% in the fourth quarter. Caitong International Asset Management Co. Ltd now owns 1,987 shares of the company's stock valued at $61,000 after acquiring an additional 1,818 shares during the period. Invesco Ltd. grew its stake in shares of Beta Bionics by 140.9% during the 4th quarter. Invesco Ltd. now owns 117,360 shares of the company's stock valued at $3,576,000 after purchasing an additional 68,640 shares during the period. XTX Topco Ltd bought a new stake in shares of Beta Bionics during the 4th quarter valued at about $1,340,000. Voloridge Investment Management LLC increased its position in shares of Beta Bionics by 549.6% during the 4th quarter. Voloridge Investment Management LLC now owns 151,647 shares of the company's stock valued at $4,621,000 after purchasing an additional 128,301 shares during the last quarter. Finally, Tudor Investment Corp ET AL increased its position in shares of Beta Bionics by 572.7% during the 4th quarter. Tudor Investment Corp ET AL now owns 259,632 shares of the company's stock valued at $7,911,000 after purchasing an additional 221,039 shares during the last quarter.
Analysts Set New Price Targets
A number of research firms have weighed in on BBNX. UBS Group upgraded shares of Beta Bionics to a "strong-buy" rating in a research note on Monday, February 9th. Robert W. Baird dropped their target price on shares of Beta Bionics from $28.00 to $14.00 and set a "neutral" rating on the stock in a research note on Wednesday, February 18th. Bank of America cut shares of Beta Bionics from a "buy" rating to a "neutral" rating in a report on Friday, January 9th. Weiss Ratings restated a "sell (d-)" rating on shares of Beta Bionics in a report on Monday, December 29th. Finally, Wall Street Zen cut Beta Bionics from a "hold" rating to a "sell" rating in a research report on Saturday, January 10th. One investment analyst has rated the stock with a Strong Buy rating, six have given a Buy rating, three have given a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, the company presently has a consensus rating of "Moderate Buy" and an average target price of $23.20.
Read Our Latest Analysis on BBNX
About Beta Bionics
(
Get Free Report)
Beta Bionics, a clinical-stage medical device company headquartered in Boston, Massachusetts, is focused on revolutionizing the management of type 1 diabetes through automated insulin delivery solutions. The company's flagship product, the iLet Bionic Pancreas system, is designed to simplify glycemic control by automatically adjusting insulin dosing in response to continuous glucose monitoring data. By integrating advanced algorithmic control with wearable infusion pumps, the iLet aims to reduce the daily burden of diabetes management and improve clinical outcomes for patients.
At the core of Beta Bionics' offering is its proprietary bionic pancreas software, which can operate in both insulin-only and dual‐hormone modes.
Read More
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
